Jazz Pharmaceuticals 2026 Third Quarter Earnings - CHIMERIX INC

Financial Performance:

• Record quarterly revenue of $1.24 billion, representing a 10% year-over-year increase; U.S. oncology revenue faced a 9 percentage point headwind due to 14 shipping weeks in Q3 2025 versus 13 in Q3 2026.
• Non-GAAP adjusted gross margin declined 110 basis points YoY due to royalties on higher sales of Medeso and Zepzelca and manufacturing tech transfers.
• Non-GAAP adjusted SG&A decreased by $132 million YoY, primarily driven by the absence of $151.5 million in antitrust litigation settlement charges from Q3 2025; excluding these, SG&A increased 6% ($19 million).
• Non-GAAP adjusted R&D expenses grew 11% due to evidence generation studies and pipeline advancement.
• Reported EPS of $(3.88) included a $754 million non-tax deductible acquired IPR&D charge from the Actio acquisition; adjusted EPS excluding this charge was positive $7.15.
• Generated $1.3 billion in operating cash flow for the first nine months of 2026; ended the quarter with $2.9 billion in cash and investments.
• Completed $820 million acquisition of Actio Biosciences; issued $1.25 billion in convertible notes and refinanced term loans.

Guidance and Future Outlook:

• Raised and narrowed 2026 total revenue guidance to $4.775–$4.85 billion (midpoint ~13% growth over 2025).
• Revised 2026 rare sleep revenue guidance to $2.125–$2.175 billion, driven by Zywave low-double-digit to low-teens growth.
• Increased 2026 non-GAAP gross margin guidance by 50 basis points to 90.5%–91.5%.
• Adjusted 2026 non-GAAP effective tax rate guidance to 19.5%–21.5% to reflect non-deductible IPR&D charges.
• Maintained share count guidance at 69–70 million shares; SG&A and R&D expense guidance remain unchanged.
• Anticipates Zyhera peak sales potential of $3–$5 billion; expects Medeso to reach $500 million in U.S. peak sales.

Business Segments and Product Lines:

• Oncology: Revenue grew 35% YoY; Zyhera generated $21 million in net sales (first-line GEA), Medeso generated ~$200 million since launch, and Zepzelca increased 32% to $104 million (second-line indication removed).
• Rare Sleep: Zywave net sales increased 12% to $483 million with 425 net patient additions; DUET trial data confirms benefits in consolidating nighttime sleep.
• Epidiolex: Net sales reached $295 million; FDA accepted NDA for new oral capsule formulation with PDUFA date of April 16, 2027.
• Pipeline: Acquired Actio Biosciences bringing ABS-1230 (KCNT1 inhibitor for epilepsy); Xanadatamab in breast cancer trial (Empower-303) expected top-line data late 2027/early 2028; initiated Phase I for JZP269 orexin-2 receptor agonist.

Market and Competitive Landscape:

• Zyhera launch shows strong community adoption, with 80% of new ordering accounts coming from community clinics and a 40% month-over-month increase in vial demand.
• Zepzelca faces future competition from Amgen's DELTA in 2027 but remains a preferred standard of care for first-line maintenance; second-line indication removal aligns with FDA.
• High-sodium oxibate generics have shown limited uptake compared to expectations, with low-sodium Zywave maintaining market share due to cardiovascular safety profile and patient support programs.
• Orexin-2 receptor agonists may cause near-term initiation delays in narcolepsy type 1 but do not address nighttime sleep fragmentation, a key Zywave differentiator.

Risks and Challenges:

• Future headwinds for Zepzelca expected in 2027 from competitor launches in small cell lung cancer.
• Potential delays in patient initiation due to the evolving landscape of orexin-2 receptor agonists entering the narcolepsy market.
• Commercial expansion of Medeso into community settings requires overcoming lower biomarker testing rates compared to academic centers.
• Zyhera adoption relies on increasing HER2 testing utilization, as current rates of eligible HER2-positive patients receiving treatment are as low as 65%.

Management Commentary and Tone:

• CEO Renee Gallup expressed strong confidence in the company's strategy, citing record revenues, successful product launches, and disciplined capital allocation.
• CCO Sam Pierce announced retirement; acknowledged building a cohesive team and achieving all three key objectives of her tenure (growth, capability building, leadership cohesion).
• CFO Phil Johnson highlighted exceptional commercial execution as the driver for consecutive guidance increases.
• Management emphasized that high sodium generics are not impacting Zywave performance as anticipated due to clinical differentiation and robust patient support services (Jazz Cares).

Analyst Questions and Answers:

• Guidance Drivers: Phil Johnson attributed guidance upside to Zywave execution (high sodium generics performing better than expected) and strong performance across Epidiolex and oncology products in the U.S. and Europe.
• Zyhera Adoption: Management clarified that the 3x increase in ordering accounts reflects new patient starts rather than switching, with 80% of new accounts from community settings.
• MEDAZO Pace: Sam Pierce noted a "measured pace" as the launch expands from academic centers to community oncology networks, with rebound in initiation rates following a summer dip.
• Orexin Strategy: Rob Anone indicated the goal is to develop a best-in-class oral solution (JZP269) for broader indications including NT2 and idiopathic hypersomnia.
• Regulatory Environment: Renee Gallup highlighted positive FDA momentum for rare disease frameworks and support for orphan drug incentives in D.C.
• Zepzelka Outlook: Confirmed 2026 revenue guidance is insulated from 2027 competitor launches, though long-term trajectory requires monitoring new data.

Other Key Points:

• Zyhera is established as a "new standard of care" with median overall survival of 27 months in the Horizon trial, the longest ever reported in first-line GEA.
• NDA submission to NCCN for Zyhera for Category 1 guideline update is underway following final Phase 3 data.
• Actio acquisition targets highly differentiated assets in rare epilepsy with fast-track, orphan drug, and rare pediatric disease designations.
• The company remains focused on the "Jazz we are building for the future" through a mix of internal innovation and strategic acquisitions like Actio.